

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer

January 4, 2016 7:15 AM ET

NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC).

"This IND filing represents an important milestone for Lion as we focus on expanding clinical applications of our core TIL technology," said Elma Hawkins, PhD, Lion's president and chief executive officer. "In a study conducted and published by the National Cancer Institute, TIL have demonstrated encouraging anti-tumor activity in cervical cancer with two patients showing durable, complete remissions out of nine patients. We are excited to be developing potentially new treatment options in these critical indications."

About Lion Biotechnologies

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit <http://www.lionbio.com>.

Forward Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
The Trout Group
Elizabeth Broder
646-378-2945
ebroder@troutgroup.com



Source: Lion Biotechnologies, Inc.

Released January 4, 2016